The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The endorsement follows overwhelming support for the share swap preceding the merger,
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The conflict is also triggering a widening public health emergency
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Subscribe To Our Newsletter & Stay Updated
